French tech company Keen Eye will bring its artificial intelligence applications to Iris Pharma, a CRO focused on ophthalmology, as part of a new collaboration.
Under the agreement, Keen Eye’s AI is expected to make assays much faster and more reliable and efficient. Iris Pharma offers preclinical and clinical services for drug and medical device development.
Financial terms of the deal weren’t disclosed.
“The advanced AI technology of Keen Eye allows us to optimize the performance of the bioimaging analysis during the preclinical ophthalmic drug development, and in the future for clinical development,” Yann Quentric, Iris Pharma’s president, said in a statement.
“We are expecting to contribute to the most challenging image-based assays to better fight eye diseases,” Keen Eye’s founder and chief executive, Sylvain Berlemont, added.
Iris, which is also headquartered in France, is a full-service research organization with a long history of helping to get ocular drugs and devices onto the market.